The term prostatitis is defined as microscopic inflammation of the tissue of the prostate gland and it occurs due to a broad range of clinical conditions. The symptoms of prostatitis include difficulty urinating, pelvic area or genitals, pain in the groin, and, sometimes, flu-like symptoms. In 2008, through various studies in the U.S., it was estimated that the prevalence of prostatitis ranges between 2.2% to 9.7%. Due to increased risk of sexually transmitted disease, people become more susceptible to prostatitis. The treatment of prostatitis depends on the underlying cause and can include, antibiotics, alpha blockers, and anti-inflammatory agents. Antibiotics is the most commonly prescribed treatment for prostatitis. The choice of antibiotics depends on the type of bacteria that might be causing the infection. Intravenous antibiotics are given in severe infections and oral antibiotics are given for four to six weeks for chronic or recurring prostatitis.
PROSTATITIS THERAPEUTICS CANDIDATES UNDER DEVELOPMENT (2017)
Ibuprofenamine has reached the Phase III stage of development for the treatment of prostatitis. It is projected that the drug would be launched commercially in coming years for the treatment of prostatitis.
As of November 2017, the prostatitis therapeutics pipeline comprises of total 11 drug candidates in various stages of development.
Some of the key players developing drugs for the treatment of prostatitis therapeutics include Angelini Acraf SpA, TFPHARMA, and Aquinox Pharmaceuticals, Inc.
Scope for Customization
P&S Market Research offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes:
Market Forecast – Market analysis and forecast for the drug candidates in the latest stage of development
Company Profiles – Wider company coverage in terms of detailed analysis or additional company profiles